Search results
Results from the WOW.Com Content Network
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. [1] It targets interferon a. [2] Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials. [3] [4] [5]
When it was introduced in 2011, it was the first new drug approved to treat lupus in 56 years. [8] Sales rose to $31.2 million in the first quarter of 2012. [37] The total cost for the first year of treatment with belimumab is $28,000. [38]
pimobendan – phosphodiesterase 3 inhibitor used to manage heart failure in dogs; pirlimycin – antimicrobial; ponazuril – anticoccidial; praziquantel – treatment of infestations of the tapeworms Dipylidium caninum, Taenia pisiformis, Echinococcus granulosus; prazosin – sympatholytic used in hypertension and abnormal muscle contractions
Ianalumab (INN; [1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjogren's disease, Immune thrombocytopenic purpura and systemic lupus erythematosus.
An exam would not cost much, but she will probably also need x-rays and blood tests, and in some cases, dogs need a CT exam or a spinal tap. If you can afford surgery, a disease like IVDD can be ...
Treatment for a lupus anticoagulant is usually undertaken in the context of documented thrombosis, such as extremity phlebitis or dural sinus vein thrombosis. Patients with a well-documented (i.e., present at least twice) lupus anticoagulant and a history of thrombosis should be considered candidates for indefinite treatment with anticoagulants.
The drug, branded as Credelio Quattro, is a single, monthly chewable tablet for dogs eight weeks of age or older, the company said. The drug is approved for the treatment of flea and tick ...